ArticleInfectious agents and cancer2025
Epidemiology of high-risk human papillomavirus among women of the north-central region of Ecuador: a retrospective study.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-risk human papillomavirus (HR-HPV) infection is the major risk factor for cervical cancer, which remains a significant concern, particularly in low and middle-income countries due to the lack of effective treatment and preventive measures. Examining the prevalence and distribution of HR-HPV is key to designing or reformulating policies aimed at eliminating HPV-associated cancers.
methodsA retrospective analysis was conducted using HR-HPV genotyping data from 9,524 women aged ≥18 years of the north-central region of Ecuador, who underwent cervical sampling either in cervical cancer prevention campaigns or during gynecological outpatient clinics, between January 2015 and August 2022. Samples were tested for HR-HPV using the cobas
resultsThe overall prevalence of HR-HPV was 26.87% [95% CI: 25.98, 27.77]. In particular, HPV 16 was found in 8.64% [95% CI: 8.08, 9.22] of the participants, HPV 18 in 2.85% [95% CI: 2.52, 3.20], and Other HR-HPV in 19.41% [95% CI: 18.62, 20.22]. Fluctuating prevalence trends during the study period were determined, with Other HR-HPV as the only category with a positive trend (aAPC: 3.44% [95% CI: 0.89, 6.05]; p < 0.01). The age-specific infection rate of HR-HPV showed a bimodal distribution, with the younger women (18-24 years old) harboring the highest rate. A second peak was identified in the postmenopausal group of 65-69 years old. Relative to Pichincha, Imbabura exhibited 50% higher odds ratio of HPV 16 infection (p < 0.001), while Santo Domingo de los Tsáchilas had 27% and 30% lower odds of Overall HR-HPV and Other HR-HPV infections, respectively (p < 0.01).
conclusionsThis study represents the largest-scale analysis on the epidemiology of HR-HPV in Ecuador. Given the high prevalence and positive trend of Other HR-HPV, our findings underscore the need for multivalent HPV vaccines. National screening strategies may consider screening of women over the age of 65 years when clinically indicated based on the patient history or physician judgment. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.